Skip to content
DataLookout
Menu

SAFENCT04563520

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

StatusWithdrawn
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 29 versions: 29 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was withdrawn because the pharmaceutical sponsor withdrew support for the study. No participants were enrolled before termination.
    • Enrollment target: estimated 5 to confirmed 0
    • Eligibility criteria shortened, about 8 words
    • Site details revised at 2 of 2 sites
  2. Notable Start date: Jun 2026 to Sep 2026v28
  3. Notable Start date: Mar 2026 to Jun 2026v27
  4. Minor Primary and study completion dates: Jan 2027 to Mar 2027
    • Start date: Jan 2026 to Mar 2026
    v26
  5. Notable Start date: Oct 2025 to Jan 2026
    • Primary and study completion dates: Sep 2026 to Jan 2027
    v25
Show 23 earlier versionsHide 23 earlier versions
  1. Notable Start date: Aug 2025 to Oct 2025v24
  2. Notable Primary and study completion dates: Sep 2025 to Sep 2026
    • Start date: Jun 2025 to Aug 2025
    v23
  3. Notable Start date: Apr 2025 to Jun 2025v22
  4. Notable Enrollment target: 20 to 5v21 Show 7 more changesShow less
    • Start date: Feb 2025 to Apr 2025
    • Eligibility criteria expanded, about 12 words
    • Primary endpoints: 3 to 1
    • Interventions: FEIBA (Drug), aPCC-emicizumab (Drug), rFVIIa (Drug) to Emicizumab (Drug), FEIBA (Drug), rFVIIa (Drug)
    • Secondary endpoints: 1 to 3
    • Study description expanded, about 51 words
    • Site contacts updated at 1 of 2 sites
  5. Notable Start date: Nov 2024 to Feb 2025v20
  6. Notable Start date: Aug 2024 to Nov 2024v19
  7. Notable Start date: Jun 2024 to Aug 2024v18
  8. Minor Start date: May 2024 to Jun 2024v17
  9. Notable Start date: Feb 2024 to May 2024v16
  10. Notable Start date: Dec 2023 to Feb 2024v15
  11. Notable Start date: Sep 2023 to Dec 2023v14
  12. Notable Start date: Jul 2023 to Sep 2023v13
  13. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 2023 to Jul 2023
    • Site details revised at 2 of 2 sites
    v12
  14. Notable Primary and study completion dates: Sep 2023 to Sep 2025
    • Start date: Mar 2023 to May 2023
    v11
  15. Notable Start date: Nov 2022 to Mar 2023v10
  16. Notable Start date: Sep 2022 to Nov 2022v9
  17. Notable Primary and study completion dates: Dec 2022 to Sep 2023
    • Start date: Jul 2022 to Sep 2022
    v8
  18. Notable Start date: Mar 2022 to Jul 2022v7
  19. Notable Start date: Dec 2021 to Mar 2022v6
  20. Minor Interventions: FEIBA (Drug), SEVENFACT (Drug), aPCC-emicizumab (Drug) to FEIBA (Drug), aPCC-emicizumab (Drug), rFVIIa (Drug)v5
  21. Notable Start date: May 2021 to Dec 2021
    • Primary and study completion dates: Sep 2022 to Dec 2022
    v4
  22. Notable Start date: Jan 2021 to May 2021v3
  23. Notable Start date: Sep 2020 to Jan 2021v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Thrombin generation capacity after aPCC (FEIBA) infusion
Timeframe: Baseline and up to 30 minutes after infusion

Secondary (3)

Number of serious adverse events
Number of serious bleeding episodes
Number of episodes of thrombotic events including thrombotic microangiopathy (TMA)

Arms and interventions

Experimental treatmentExperimental

Participants will have a first/baseline thrombin generation assay (TGA) sample (to be processed within 60 minutes), followed by an infusion at 15 U/kg dose of aPCC, and provide a second TGA sample 15-30 minutes after to be processed within 60 minutes. If required, a subsequent TGA sample will be obtained upon a 25 U/kg dose of aPCC to be processed within 60-90 minutes.

Drugs: Emicizumab, FEIBA, rFVIIa

Sites

2 sites in 1 country